Semaglutide and Tirzepatide as Adjunctive Therapy Show No Benefit for IBD Relapse in Obese/Diabetic Patients
Background
Patients with Inflammatory Bowel Diseases (IBD), encompassing Crohn's disease and ulcerative colitis, often suffer from comorbidities like obesity and type 2 diabetes. These conditions can complicate IBD management and worsen patient outcomes. While GLP-1 Receptor Agonists (GLP1RAs) like semaglutide and tirzepatide are highly effective for weight loss and glycemic control, their potential impact as adjunctive therapy on IBD-specific outcomes, such as inflammation and relapse risk, remains unclear. This study addresses whether these agents offer additional benefits beyond their metabolic effects in this complex patient population.
Study Design
Researchers conducted a target trial emulation using observational data from the OptumLabs Data Warehouse (2018-2023) to assess GLP1RA initiation in stable IBD patients with comorbid obesity and/or diabetes. Patients were eligible if they had no steroid use, IBD-related hospitalization, or surgery, and were on stable IBD therapy for >6 months. Two cohorts were created: (1) those on background 5-ASA or no IBD-directed medications, and (2) those on advanced therapies and/or immunomodulators. They compared 1-year risk of relapse (IBD-related hospitalization, surgery, or prednisone use) and safety outcomes between GLP1RA initiators vs. non-initiators after 1:1 propensity score matching.
Results
In Cohort 1, 2028 patients initiated on GLP1RAs (mean age 63±11y, 63% female, 71% with ulcerative colitis) were matched to non-initiators. No significant difference in relapse risk was observed (7.9% vs. 7.9%; RR, 1.01 [95% CI, 0.82-1.24]), nor in safety outcomes (7.0% vs. 7.9%; RR, 0.88 [0.71-1.10]). Notably, 36% of patients discontinued GLP1RAs within 1 year.
For Cohort 2, involving 346 patients on advanced therapies or immunomodulators (mean age 59±12y, 62% female, 43% with ulcerative colitis), matched 1:1 to non-initiators, no significant difference was found in relapse risk (12.4% vs. 15.6%; RR, 0.80 [0.55-1.15]) or safety outcomes (5.5% vs. 6.6%; RR, 0.88 [0.48-1.58]). Discontinuation rates were similar at 33% within 1 year.
Key Findings
- Adjunctive GLP1RA therapy (semaglutide or tirzepatide) did not reduce IBD relapse risk in stable patients with obesity/diabetes.
- Cohort 1 (5-ASA/no IBD meds): Relapse risk was 7.9% for GLP1RA initiators vs. 7.9% for non-initiators (RR, 1.01 [95% CI, 0.82-1.24]).
- Cohort 2 (advanced therapies/immunomodulators): Relapse risk was 12.4% for GLP1RA initiators vs. 15.6% for non-initiators (RR, 0.80 [95% CI, 0.55-1.15]).
- No significant difference in safety outcomes was observed in either cohort.
- GLP1RA discontinuation rates were high, at 36% in Cohort 1 and 33% in Cohort 2 within 1 year.
Why It Matters
This study provides crucial real-world evidence for clinicians managing IBD patients with obesity and/or diabetes. Adjunctive semaglutide or tirzepatide does not appear to offer additional benefit for IBD-specific outcomes like relapse prevention, regardless of background IBD therapy. This suggests that while these GLP1RAs are valuable for their metabolic indications, they should not be prescribed with the expectation of improving IBD disease activity. Patients and practitioners should focus on the primary metabolic benefits when considering these drugs, rather than anticipating an anti-inflammatory or disease-modifying effect on IBD itself. The high discontinuation rates also highlight potential tolerability challenges in this population.
semaglutide
tirzepatide
ibd
obesity
diabetes
glp-1-agonist